Monte Rosa Therapeutics Stock Today
| GLUE Stock | USD 8.57 0.21 2.51% |
Performance6 of 100
| Odds Of DistressLess than 31
|
Monte Rosa is trading at 8.57 as of the 21st of November 2024, a 2.51 percent increase since the beginning of the trading day. The stock's lowest day price was 8.05. Monte Rosa has about a 31 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Monte Rosa Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of June 2021 | Category Healthcare | Classification Health Care |
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the bodys natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics, Inc. The company has 61.44 M outstanding shares of which 7.84 M shares are currently shorted by private and institutional investors with about 1.65 trading days to cover. More on Monte Rosa Therapeutics
Moving against Monte Stock
| 0.74 | PALI | Palisade Bio | PairCorr |
| 0.66 | INZY | Inozyme Pharma | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.64 | KTTA | Pasithea Therapeutics | PairCorr |
| 0.63 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
| 0.61 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Monte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Markus MD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMonte Rosa can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Monte Rosa's financial leverage. It provides some insight into what part of Monte Rosa's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Monte Rosa Therapeutics (GLUE) is traded on NASDAQ Exchange in USA. It is located in 321 Harrison Avenue, Boston, MA, United States, 02118 and employs 133 people. Monte Rosa is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 513.61 M. Monte Rosa Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 61.44 M outstanding shares of which 7.84 M shares are currently shorted by private and institutional investors with about 1.65 trading days to cover.
Monte Rosa Therapeutics currently holds about 294.14 M in cash with (43.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.32.
Check Monte Rosa Probability Of Bankruptcy
Ownership AllocationMonte Rosa Therapeutics maintains a total of 61.44 Million outstanding shares. The majority of Monte Rosa outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Monte Rosa Therapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Monte Rosa Therapeutics. Please pay attention to any change in the institutional holdings of Monte Rosa as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Monte Ownership Details
Monte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Vestal Point Capital Lp | 2024-06-30 | 890 K | |
| Geode Capital Management, Llc | 2024-06-30 | 847.4 K | |
| State Street Corp | 2024-06-30 | 636.1 K | |
| Exoduspoint Capital Management, Lp | 2024-09-30 | 393.6 K | |
| Sphera Funds Management Ltd. | 2024-06-30 | 375 K | |
| Northern Trust Corp | 2024-09-30 | 358.6 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 346.5 K | |
| Renaissance Technologies Corp | 2024-09-30 | 218.7 K | |
| Td Asset Management Inc | 2024-09-30 | 193.7 K | |
| Nea Management Company, Llc | 2024-06-30 | 7.7 M | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 6 M |
Monte Rosa Historical Income Statement
Monte Stock Against Markets
Monte Rosa Corporate Management
| Filip MD | Chief Officer | Profile | |
| Jennifer Champoux | VP Operations | Profile | |
| Sharon Townson | Chief Officer | Profile | |
| Edmund Dunn | Vice Controller | Profile | |
| John Castle | Chief Scientist | Profile | |
| Magnus DPHIL | Senior Development | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.221 | Return On Assets (0.28) | Return On Equity (0.61) |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.